home.aspx
 
EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

RELATED NEWS


PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals as a very limited distribution partner for the novel drug GIVLAARI™ (givosiran). GIVLAARI is the first and only FDA-approved medicine indicated for the treatment of adults with Acute Hepatic Porphyria (AHP). GIVLAARI becomes the second RNAi therapeutic from Alnylam approved by the FDA in the last 16 months and the first-ever approved GalNAc-Conjugate RNA therapeutic, a landmark in the advancement of ...

READ MORE

Despite releasing positive data on its Phase III ENVISION trial, Alnylam Pharmaceuticals stock dropped 7.5 percent. Although not completely clear why the drop may be related to a high percentage of serious adverse events observed in the trial. The ENVISION Phase III trial evaluated givosiran, an investigational RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP). AHP is a family of rare, genetic diseases characterized by possibl...

READ MORE

Gene therapy has become one of the hottest areas of biotech research. Some gene therapies, like Spark Therapeutics’ eye drug Luxturna, deliver healthy genes to replace mutated ones, while others, such as Alnylam Pharmaceuticals’ RNA interference therapy Onpattro, work by silencing disease-causing genes. But controlling the strength and timing of gene expression with these therapies has proven challenging, especially when RNA is the central mechanism at work.
A group of Massach...


READ MORE

EVENTS

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...